Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Related Articles by Review for PubMed (Select 22917634)

1.

Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches.

Renoir JM.

Steroids. 2012 Oct;77(12):1249-61. doi: 10.1016/j.steroids.2012.07.019. Epub 2012 Aug 11. Review.

PMID:
22917634
2.

Estrogen receptor signaling as a target for novel breast cancer therapeutics.

Renoir JM, Marsaud V, Lazennec G.

Biochem Pharmacol. 2013 Feb 15;85(4):449-65. doi: 10.1016/j.bcp.2012.10.018. Epub 2012 Oct 24. Review.

PMID:
23103568
3.

Cell proliferation regulated by estradiol receptor: Therapeutic implications.

Castoria G, Migliaccio A, Giovannelli P, Auricchio F.

Steroids. 2010 Aug-Sep;75(8-9):524-7. doi: 10.1016/j.steroids.2009.10.007. Epub 2009 Oct 30. Review.

PMID:
19879889
4.

Estrogen receptors: selective ligands, partners, and distinctive pharmacology.

Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA.

Recent Prog Horm Res. 2000;55:163-93; discussion 194-5. Review.

PMID:
11036937
5.

Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.

Shibata H, Spencer TE, Oñate SA, Jenster G, Tsai SY, Tsai MJ, O'Malley BW.

Recent Prog Horm Res. 1997;52:141-64; discussion 164-5. Review.

PMID:
9238851
6.

Estrogen receptors and their downstream targets in cancer.

Ikeda K, Inoue S.

Arch Histol Cytol. 2004 Dec;67(5):435-42. Review.

7.

Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.

Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W, Berstein L.

Endocr Relat Cancer. 2003 Jun;10(2):111-30. Review.

8.

Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.

Fox EM, Andrade J, Shupnik MA.

Steroids. 2009 Jul;74(7):622-7. doi: 10.1016/j.steroids.2008.10.014. Epub 2008 Nov 5. Review.

9.

Proliferation of breast cancer cells: regulation, mediators, targets for therapy.

Mester J, Redeuilh G.

Anticancer Agents Med Chem. 2008 Dec;8(8):872-85. Review.

PMID:
19075570
10.

Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.

Pasqualini JR, Chetrite GS.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36. Review.

PMID:
15860265
11.

How to target estrogen receptor-negative breast cancer?

Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M.

Endocr Relat Cancer. 2003 Jun;10(2):261-6. Review.

12.

Targeted therapy of metastatic breast cancer.

Sánchez-Muñoz A, Pérez-Ruiz E, Jiménez B, Ribelles N, Márquez A, García-Ríos I, Alba Conejo E.

Clin Transl Oncol. 2009 Oct;11(10):643-50. Review.

PMID:
19828406
13.

Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

Ciocca DR, Gago FE, Fanelli MA, Calderwood SK.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):32-40. Epub 2006 Oct 17. Review.

PMID:
17049840
14.

The role of mitogen-activated protein (MAP) kinase in breast cancer.

Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W.

J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56. Review.

PMID:
11897507
15.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
16.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
17.

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.

Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, Mérand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):51-84. Review.

PMID:
10418981
18.

Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.

Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):477-86. Review.

PMID:
14623547
19.

Structure-function relationship of estrogen receptor alpha and beta: impact on human health.

Ascenzi P, Bocedi A, Marino M.

Mol Aspects Med. 2006 Aug;27(4):299-402. Epub 2006 Aug 17. Review.

PMID:
16914190
20.

Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans.

Skandalis SS, Afratis N, Smirlaki G, Nikitovic D, Theocharis AD, Tzanakakis GN, Karamanos NK.

Matrix Biol. 2014 Apr;35:182-93. doi: 10.1016/j.matbio.2013.09.002. Epub 2013 Sep 21. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk